To enhance their therapeutic efficacy, NK-92 cells have been modified to express CARs against different cancer targets, including CD20 for lymphoma and leukemia, CD19 for chronic lymphocytic leukemia (CLL), GD2 for neuroblastoma, and EpCAM for breast carcinoma [22]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.